Ajmaline
As of the edition of 20 October 2026, Ajmaline is a small molecule: marketed; acts on KCNA5, KCND3 and SCN5A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Gilurytmal
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Carinopharm Gmbh; 2 holders in all
- Registered trials
- 5, 0 stopped early
- Disease areas
- Heart and blood vessels; Inherited and neonatal; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 5 |